Boston Scientific SYNERGY Everolimus-Eluting Platinum Chromium Stent

Register to receive a free U.S. Market for Interventional Cardiology Devices report synopsis and brochure

A newly approved stent designed to provide advanced treatment is now being used for patients undergoing cardiac catheterizations, a medical procedure used to diagnose and treat some heart conditions, at Shannon Medical Center. Shannon’s interventional cardiologists are now treating their patients with the SYNERGY Everolimus-Eluting Platinum Chromium Stent that hit the market after being approved by the U.S. Food and Drug Administration for commercial distribution in October.

The technology is produced by Boston Scientific, a developer, manufacturer and marketer of medical devices. Shannon is the first hospital in the Concho Valley and one of the first in Texas to use the stent, said Rudy Haddad, interventional cardiologist at Shannon. There are thousands of labs that do interventions and there are roughly about 200 labs that are using this stent now. Shannon is one of those 200 labs nationwide, he said.

Stents are tiny mesh tubes doctors use to prop open clogged arteries, allowing blood to flow freely to the heart. Stents are inserted into an artery through a small catheter using a pathway from the wrist or the groin, according to a Shannon news release. The hospital began using the SYNERGY stents last week, and cardiologists have already treated several patients.

“We use the newest drug eluting stents and bare metal stents when needed,” Haddad said about the type of stents the hospital offers its patients. “This is the newest generation; the partially bioabsorbable stent is the first to market. The newly designed stent has a bio-absorbable polymer that is absorbed in 2 to 3 months after the drug has been released, which can result in reducing the possibility of an inflammatory reaction to the polymer, and has the potential in the future to better benefit patients taking blood thinners after a procedure, he said.”

The SYNERGY stent is being studied in more than 15,000 patients worldwide, and has documented outstanding safety and efficacy of the Bioabsorbable Polymer Everoliums Eluting Platinum Chromium Stent, the release stated. More than 1,200 cardiac catheterizations are performed at Shannon each year with the majority of them being drug coated stents.

“Haddad said patients that can benefit from the news stents will shift from the formerly used drug coated stents. Shannon’s heart team offers world-class cardiac care by using the most state of the art technology to help people here in San Angelo and the Concho Valley that come to us, he said. The hope is, as these new generation of stents are been designed, they get better and easier to use by reducing complications and damage to the artery, lessening the need for emergent bypasses and offering more success rates, he said.”

For Further Information
More on the interventional cardiology market in the U.S. can be found in the report published by iData entitled U.S. Market for Interventional Cardiology Devices. This report also covers the U.S. market segments for bare-metal and drug-eluting stents, PTCA and cutting balloons, balloon-inflation devices, interventional coronary catheters, interventional coronary guidewires, coronary embolic protection devices, coronary atherectomy devices, coronary thrombectomy devices, coronary chronic total occlusion crossers, introducer sheaths, coronary vascular closure devices, diagnostic coronary catheter and guidewires, intravascular ultrasound catheters, and optical coherence tomography catheters.

The iData series on the market for interventional cardiology devices covers the U.S., Japan, Brazil, and 15 countries in Europe. Full reports also provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment. To find out more about U.S interventional cardiology market data or procedure data, register online or email us at [email protected] for a U.S. Market for Interventional Cardiology Devices report brochure and synopsis.

About Procedure Tracker
Procedure number data is available from iData’s Procedure Tracker service, which allows subscribers to define and analyze procedure data segmented by state, region, hospital, surgery centre, and physician. A customizable dashboard sorts procedure data for further analysis and research.

About Reimbursement Tracker
iData Research’s Reimbursement Policy Tracker enables medical device, dental, pharmaceutical and healthcare professionals to receive real-time policy updates from hundreds of insurance companies and 60,000+ policies across all therapeutic areas in the United States.


Explore our careers page for our current available job opportunities. This is your chance to join a fun and dynamic team in the medical market research industry. Send your resume to [email protected] with the job title in the subject line, and feel free to tell us a little about yourself. We look forward to hearing from you.

Like us on Facebook: facebook.com/iDataResearch
Follow us on LinkedIn: linkedin.com/company/idata-research
Follow us on Twitter: twitter.com/iDataResearch